AU2011217530B2

AU2011217530B2 - Pharmaceutical comprising myramistin

Info

Publication number: AU2011217530B2
Application number: AU2011217530A
Authority: AU
Inventors: Adolina Rudko
Original assignee: MEGAINPHARM GmbH
Current assignee: MEGAINPHARM GmbH
Priority date: 2010-02-19
Filing date: 2011-02-15
Publication date: 2014-01-16
Anticipated expiration: 2031-02-15
Also published as: MD4411B1; ES2524379T3; HK1179164A1; MD20120079A2; WO2011100994A1; PL2536400T3; JP5746224B2; MX2012009646A; MD4411C1; JP2013519695A; EP2536400B1; GEP20135942B; DK2536400T3; BR112012020828A2; HRP20141173T1; KR101744895B1; CY1115833T1; UA103968C2; EA022283B1; PT2536400E

Abstract

The invention relates to a pharmaceutical including benzyldimethyl(3-[myristoylamino]propyl)ammonium chloride in the monohydrate form or in unhydrated form. The pharmaceutical further comprises dimethyl(3-[myristoylamino]propyl)ammonium oxide and/or dimethyl(3-[myristoylamino]propyl)amine in the appropriate pharmaceutical solvent.

Description

1 PHARMACEUTICAL PREPARATION COMPRISING MYRAMISTIN [0001] The invention relates to the field of medicine and the pharmaceutical industry. It can be used in the development, preparation and use of healing and prophylactic preparations for humans and animals. [0002] The synthesis and the use of quaternary ammonium salts which simultaneously contain an amide group were first described in US Patent 2,459,062 (reference 1). In particular, in Example 1, the synthesis of [myristamido]propyl)dimethylbenzylammonium chloride by the reaction of [(myristoylamido)propyl]dimethylamine with benzyl chloride in benzene. [0003] In that patent, the activity of the prepared product with respect to the standard Staf strain is demonstrated. At room temperature, the product described by the inventors is a semi-hard substance with a melting temperature of 54'C (column 3, lines 69-70). In Example 1, no other investigations that would confirm the structure of the product obtained are mentioned. However, the investigations according to the invention with regard to the isolation of a pure preparation suitable for medical use show that [myristamido]propyl)dimethylbenzylammonium chloride at room temperature is a crystalline substance with a melting temperature of over 90 0 C. [0004] Hence it can be assumed that the inventors have obtained the mixture of the primary product and the solvent (benzene) and have investigated their effectiveness. Nevertheless, using such a product for medical purposes is impossible, because of the toxicity of benzyl chloride and benzene. [0005] According to column 3, line 62, the fundamental [(myristamido)propyl]diethylamine is also a solid, as is also proved by the investigations according to the invention. For that reason, the product obtained in Example 1 cannot be a mixture of the fundamental amidoamine and the final compound. Moreover, the presence of the residues of the fundamental amidoamine is impossible, since in Example 1 an adequate quantity of benzyl chloride is used in the reaction. [0006] It should also be mentioned that pure ([myristamido]propyl)dimethylbenzylammonium chloride in water does not yield a solution with a concentration of over 20%, and that the fundamental [(myristoylamido)-propyl]dimethylamine does not dissolve in water at all and is 2 separated out of other solutions into other solvents by means of water. This is also evidence that the final product of Example 1 cannot contain an admixture of [(myristamido)propyl]dimethylamine, since in column 3, lines 73-74, reference is made to the preparation of the transparent 25% water solutions. [0007] A number of pharmaceutical preparations on the basis of benzyldimethyl-(3 [myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form are known. These pharmaceutical preparations serve to treat and prevent certain kinds of diseases (SU 1796185 (reference 2), EP 1634590 (reference 3), WO 93/00892 (reference 4), RU 2157214 (reference 5), US 67795 (reference 6), RU 2161961 (reference 8), RU 2188005 (reference 13), RU 2184534 (reference 14), RU 2164135 (reference 15), RU 2177314 (reference 16), RU 2185157 (reference 17), RU 2173142 (reference 19), and UA 30143 (reference 20)). The inadequacy of these pharmaceutical preparations resides either in a very limited range of effectiveness of the particular solution or in insufficient efficiency in comparison to the proposed technical solution. Some concrete, but not exhaustive, comparative indications are listed in the Examples of the present specification. [0008] Further proposals contemplate the use of tertiary amines ion the biologically active compounds. These amines contain the amide group, including dimethyl-[3 (myristoylamino)propyl]amine ([(myristamido)propyl]dimethylamine) (for example, US WO 2007/136558) (reference 10). Such compounds in the composition with polyhexamethylene biguanidine are used in multi-component compositions for disinfecting various surfaces. However, at such concentrations they cannot be used as pharmaceutical preparations because of their high toxicity. US 2004/0058924 (reference 9) shows the possibility of using the amidoamines in the compositions for treating a purely fungal infection of the eyes and of using their combination with acanthamoeba. In US patent application 2004/0033208 (reference 21), it is proposed that the amidoamines be used in a composition with antibiotics for treating and preventing fungal diseases of the eyes and the nose. However, the efficiency of these compositions is poor in bacterial infections, and they cannot be used for treating internal organs or for example as spermicidal preparations. [0009] In WO 95/08266 (reference 22), it is proposed that the amidoamines of such a type be used in corresponding compositions for cleaning contact lenses. However, these compositions 3 cannot be used for treating diseases of the eyes or of the ears and throat, for example. Nor can they be used in intracavity operations or as a means of prophylaxis of sexually transmitted diseases, since they comprise multiple components and have a high concentration of the components. [0010] The use of amine oxides of this type is described in US Patent 4,093,711 (reference 11). In that patent it is proposed that 1% aqueous water solutions of various amine oxides, in particular dimethylaminopropyl myristamide N oxide, be used in the compositions for hygienically cleaning teeth, to make it easier to remove tartar and prevent the formation of tartar. In that case, the amidoamine oxide used performs the function of a softening agent and emulsifier of the plaque and is not a pharmaceutical preparation. [0011] We have not been able to find pharmaceutical compositions in which amidoamine oxides and simultaneously quaternary ammonium salt and tertiary amidoamine and/or oxide of that amine in the accessible sources in the literature. [0012] The prior art that is closest to the present invention is the pharmaceutical preparation disclosed in Eurasian patent 005132 (reference 23). It comprises the quaternary ammonium compound of benzyldimethyl-(3-[myristoylamino]propyl)ammonium chloride ([myristamido]propyl)dimethylbenzylammonium chloride) in the form of monohydrate. As its pharmaceutically dissolving agent, this pharmaceutical preparation contains water and/or alcohol, for liquid forms of the preparation. In other forms of administration of the pharmaceutical preparation, it contains an arbitrary base of vegetable, animal or synthetic origin. The preparation has good antimicrobial and antimycotic efficiency. The antibacterial effect of the pharmaceutical preparation during the in vitro experiments was rather high. However, its efficiency drops off substantially when various compositions are used for prophylaxis and treatment in vivo, under the influence of a high protein load. On the other a substantial increase in concentration intensifies the resultant irritation. Also, this pharmaceutical preparation cannot be effectively combined with some bases and pharmaceutical preparations with a different intended effect, because then complex compounds are formed that settle out. [0013] As a pharmaceutical preparation for the treatment and prophylaxis of diseases of various origin in humans and animals, the following composition is proposed: 4 benzyldimethyl-(3-[myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form, with dimethyl-(3 [myristoylamino]propyl)ammonium oxide and/or dimethyl-[3 (myristoylamino)propyl]amine in the appropriate pharmaceutical solvent. [0014] For external use, given acceptable toxicity, the composition has the greatest efficiency at the following proportion of components (in weight %): benzyldimethyl-(3-[myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form 0.008 to 5.0 dimethyl-(3-[myristoylamino]propyl)ammonium oxide and/or dimethyl-[3-(myristoylamino)propyl]amine 0.00005 to 1.0 an appropriate pharmaceutical solvent up to 100. [0015] The composition for application to the mucous membrane or for intracavity use has the least irritation and toxicity for humans and animals and adequate efficiency at the following proportion of components (in weight %): benzyldimethyl-(3-[myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form 0.008 to 2.0 dimethyl-(3-[myristoylamino]propyl)ammonium oxide and/or dimethyl-(3-[myristoylamino)propyl]amine 0.00005 to 0.01 an appropriate pharmaceutical solvent up to 100. [0016] As the pharmaceutical solvent, it is proposed that water and/or alcohol and an arbitrary liquid, gel-like salve base, detergent base or solid base of vegetable, animal or synthetic origin be used, depending on the mode of administration and on the site where it is used. [0017] A great number of combinations of this pharmaceutical preparation with pharmaceutical preparations of different effect is also proposed. The pharmaceutical preparations with a different effect include for example local anesthetics (lidocaine, bupivacaine, pyromecaine, or trimecaine), sodium chloride, anti-edematous agents (xylometazoline, oxymetazoline, naphazoline, 5 phenylephrine, phenylpropanoloamine or pseudoephedrine) or corticosteroids (triamcinolone, betamethasone or fluocinolone acetonide, hydrocortisone, halomethasone, or dexamethasone), antiseptics and/or viricidal preparations (metronidazole, clotrimazole, ketoconazole, acyclovir or rimantidine). [0018] The present invention makes it possible to expand the manifold means of prophylaxis and treatment. These means have a broad spectrum of effectiveness and high efficiency, low irritation and toxicity, and an immune-modulating, anesthetic, anti-edematous and infection-inhibiting effect. This makes it possible to employ the pharmaceutical preparation for a greater number of diseases. The preparation is recommended as a means for treatment and prophylaxis of infectious and inflammatory diseases. These also include both specific and nonspecific diseases of the urogenital system, the gastrointestinal area, and of the nose and throat and the eyes. It is also suitable as a means for prophylaxis of sexually transmissible diseases, such as herpes and HIV infection and as a spermicidal, antiseptic and disinfecting means. [0019] When the ingredients used are employed in common, the present technical solution has brought to light a surprising synergistic effect, which cannot be obvious from the known art. [0020] The effectiveness of the present preparation and the effect ascertained will be described in terms of the following, non-limiting examples. Example 1 [0021] For documenting the present technical solution, various variants of the compositions of the preparation of this patent application are used. In Table 1, some of the compositions investigated are show, specifically those that were used in the Examples discussed below. Table 1 Variants of the compositions (in weight %) [headings left to right:] 6 Composition (Z) No. Benzyldimethyl-(3-[myristoylamino]propyl)ch (Ach) Dimethyl-[3-(myristoylamino)propyl]ammonium oxide (AO) Dimethyl-[3-(myristoylamino)propyl]ammonium oxide (AA) Solvent up to 100 Zi 0.007 0.001 - Pure water Z2 0.01 0.001 - Isotonic NaCl solution Z3 0.4* 0.01 0.01 Hydrophilic salve base Z4 1.5 0.5 - Pure water Z5 0.1 0.05 - Isotonic NaCl solution Z6 0.006 0.001 - Pure water Z7 0.5* 0.01 0.1 Hydrophilic salve base Z8 0.5 - 0.01 Aerosol Z9 0.1* - 0.01 70% Ethanol Z10 0.04 0.0-1 - Pure water Z11 0.05* 0.01 0.01 Suppository compound Note: * Monohydrate 7 Example 2 [0022] Ascertaining minimal inhibition concentrations (MICs) with regard to a test culture of corona viruses (human corona viruses OC43) in vitro on a human embryo kidney cell culture. The composition ZI (two components in the proportion of 6:1) and as a prototype for comparison the preparation according to reference 3 (pure benzyldimethyl-(3 myristoylamino]propyl)ammonium chloride) and pure dimethyl-[3 (myristoylamino)propyl]amine oxide (AA) were used. The investigation was done in parallel by the following scheme: 1 t stage Test virus + myramistin (in suitable concentration 2 " stage Incubation (2 hours) 3 rd stage Admixing the neutralizing substance (such as 25% embryo serum from cows) of the composition and incubating the composition for 10-20 min. 4 th stage Infecting the vulnerable cell cultures (such as human embryo kidneys) 5 th stage Incubation (5-8 days) 6 th stage Detecting the results with regard to hemadsorption and cytopathic effet and symplast formation [0023] Three series of experiments, each at four dilutions of the preparation, were performed. Next, the applicable MIC for corona viruses was ascertained. The results of the experiments are shown in Table 2. Table 2 MIC of preparation per this patent application and of other antiseptics for human corona virus OC43 in vitro 8 Antiseptics MIC (%) Zi 0.007 ± 0.002 D3 (Ach) 0.01 + 0.005 AO 0.1 ± 0.05 [0024] As can be seen from the figures in Table 2, Z1 is superior in its inactivation effect on the corona viruses to both individual preparations and exhibits a synergistic effect. Example 3 [0025] The local irritation caused by the preparation of this patent application on the skin and connective tissue membrane and the vaginal mucous membrane was investigated using guinea pigs and rabbits. The local irritation of the mucous membrane of the urethra and bladder was investigated using dogs. [0026] The figures found demonstrate that applications of compositions Z4 and Z9 to the skin caused neither visible nor histological changes over the course of 40 days. Increasing the total concentration of the ingredients in the preparation up to 5.0 weight % caused slight xeroderma and insignificant atrophy of the epidermis by the 3 0 th day of applications. [0027] At the same time, in reference 8, 20 and 23, the solutions of pure Ach already caused skin irritation at concentrations of over 1 weight %, and higher concentrations (2 to 3 weight %) by the 10 th to the 15th day brought about substantially greater skin changes. [0028] When the 0.01% solution of pure AA in 70% alcohol was applied, skin irritations were already apparent by the 1 0 th day. [0029] The solution of the composition of this patent application (Z5) in the isotonic solution of sodium chloride was dripped into the eyes of rabbits and guinea pigs over the course of 10 days with total concentrations of the ingredients of 0.15 weight %. There were no irritant effects on the mucous membranes (assessment by the Draise scale = 0; assessment by the Ogur classification: group A). At the same time, the concentration of the preparation according to 9 reference 23 of over 0.05 weight % caused irritations of the connective tissue membrane (on the Draise scale - 8 to 10 points; assessment by the Ogur classification = group B). [0030] 20 ml each of the 0.05% solution of the composition of this patent application (AZ, Z10) in water were dripped four times a day, over the course of 10 days, into the urethras of male dogs. After this treatment, no changes in the animals' behavior were observed. Urinalysis, blood tests, and histological investigation of the mucous membrane of the urethra, bladder and other organs of the dogs showed no deviations from the norm. [0031] Nor were any morphological or histological deviations in the vaginal mucous membrane of the female animals found when Z7 and Z8 (the salve and the aerosol) were instilled. [0032] At the same time, references 4, 8 and 23 already show irritation at concentrations that are 2 to 5 times lower, which proves the presence of synergistic effects. Example 4 [0033] Research into the spermicidal effect was done by one of the methods recommended by WHO. For this, human spermatozoa were mixed with various concentrations of the AZ. Next, the motility of the spermatozoa was checked using the microscope. Still other parameters (pH, reduction of methylene blue, checking the contact with cervical mucus, fructose level, and others) were also researched. In all, 17 spermatozoa from men aged 18 to 23 were investigated. The experimental results have shown that the optimal concentration of the preparation of this patent application, that is, the concentration at which the motility of the spermatozoa ceases within 20 seconds, is 0.02 weight %. Higher concentrations of the preparation not only cause instantaneous immobility of the spermatozoa but also spermatolysis. Example 5 [0034] The prophylactic effect of the preparation of this patent application in sexually transmitted diseases was investigated using experimental syphilis in rabbits as the model. The experiments were performed on 56 rabbits of the chinchilla breed. The rabbits were infected with a freshly prepared suspension of pale spirochetes (Nichols strain and ZKVI-8 (Zentrales Institute 10 fir Haut- und Geschlechtskrankheiten [Central Institute for Skin and Sexually Transmitted Diseases]) by an epicutaneous method. At 30, 60, 120, 180 and 240 minutes after the infection, the skin of the affected area was treated with Z6 or reference 23. The rabbits from the control group were treated with distilled water. All the animals were under clinical and serological control for 6 to 12 months. For the control, the Wassermann reaction (RW), the treponema immobilization test, and the immunofluorescence reaction were used. They were done every 2 to 3 months, beginning 1.5 months after the infection. The methods of passivation of lymph nodes and reinfection of the scrotal skin with the suspension of spirochetes from the same strain were also used. The experimental results showed that processing test rabbits with Z6 and reference 23 within from 30 minutes to 2.5 hours after the moment of infection led to 100% protection of the animals against syphilis. At the same time, for reference 23, the concentration below 0.01% does not yield a 100% result more than 30 minutes after the moment of infection. Example 6 [0035] The healing effect on models of purulent wounds and peritonitis in test animals (rats, rabbits, guinea pigs, dogs; in all, over 100 animals) was researched using widely approved methods. Bacteriological, morphological, histological and immunological investigating methods were employed. [0036] The figures obtained showed a high therapeutic activity of ZA. AZ is used in the forms of an aqueous solution, a salve, and an aerosol for purulent inflammatory diseases and peritonitis in test animals. AZ proved to be a much more effective preparation for treating purulent wounds in comparison to the prototype and to pure ingredients (Table 3). Table 3 Effect of the AZ on healing purulent wounds in test animals (rats, guinea pigs, rabbits) in comparison to the prototype and to pure ingredients. (in days) Animal Groups Onset of regeneration Complete healing 11 Control (wound healing 7.2 1.1 20.0 ± 3.5 using distilled water) Treatment with reference 23 3.5 0.7 12.7 ± 1.3 Treatment with Z7 2.3 + 0.3 9.4 ± 0.9 Treatment with Z8 2.1 + 0.3 9.2 ± 0.9 Treatment with Z10 2.2 0.3 9.3 ±0.9 0.1% aqueous solution AO 6.1 ± 1.1 18.9 ± 3.5 0.1% aerosol AA 5.2 ±1.3 17.0 ±3.1 Example 7 [0037] The healing effect of the preparation of this patent application on burn models in mice was investigated. Contact heat burning was done on the depilated dorsal surface of the back of the mice using a commercially available device. The treatment was begun 24 hours after the burning. A salve and an aerosol (Z7 and Z8) were use. For comparison, references 6 and 17 were employed according to the prototype. The results are shown in Table 4. [0038] From the figures in Table 4 it can be concluded that reliable reduction in the wound surface area with treatment with Z7 and Z8 begins after eight days. This is four days earlier than with reference 6 and reference 17. It can be asserted that this reduction can be ascribed to synergistic effects. Table 4 Results of planimetry of burn wounds treated with salve and aerosol 12 Days Surface area of burn wounds in square cm References 6 and 17 Z7 Z8 2 0.72 ± 0.05 0.80 ± 0.06 0.99 ± 0.08 4 0.77 ± 0.66 0.85 ± 0.07 0.81 ± 0.09 6 0.80 ± 0.05 0.85 ± 0.09 0.62 ± 0.06 8 0.78 ±0.10 0.83 ±0.10 0.76 ±0.07 12 0.81 ± 0.05 0.70 ± 0.06 0.24 0.04 15 0.36 ± 0.05 0.18 ± 0.03 0.14 ± 0.03 18 0.14 ±0.04 0.08 ±0.02 0.03 ± 0.017 20 0.03 ±0.017 0.012 ±0.002 0.01 ±0.001 Example 8 [0039] The effect on purulent and inflamed affections of the cornea was investigated. The experiments were performed on 16 rabbits of the chinchilla breed. The rabbits' weight ranged from 2 to 2.5 kg. The purulent and inflammatory effects on the cornea were caused by the administration into the cornea of a suspension of a 24-hour culture of Staphylococcus aureus, strain 209 P. On the second to fourth day, ulcers appeared on the cornea of 13 rabbits. The ulcers measured 3 x 6 mm and had a purulent discharge at their base. At the same time, inflammatory reactions were observed: conjunctivitis, blepharospasm, and others. [0040] The rabbits selected for the experiment were divided into three groups. The animals in the first group were treated with Z2. The animals in the second group were treated with eye drops according to references 7 and 15 (eye drops per prototype, ATP). Drops of an isotonic solution of sodium chloride were instilled in the affected eyes of the animals in the third group. The preparations were instilled three times a day over the course of the entire experiment. [0041] All the animals were observed daily. The course of the change in the cornea in the test animals and control animals was checked by the methods described above. Inoculations of rinses of the corneas of the rabbits were also placed in meat broth and peptone nutrient media in order 13 to ascertain the presence of the S. aureus strain 209 P. The results of these experiments are shown in Table 5. Table 5 Results of treatment of purulent and inflammatory affections of the cornea in rabbits [column headings, left to right:] Features of the therapeutic effect Animal group number Frequency of finding features of the therapeutic effect in the cornea (in %) after the monitoring time (in days): ** [First column, top to bottom:] Absence of the purulent discharge in the eyes Absence of S. aureus in the purulent discharge in the eyes Resorption of the pus infiltrate Epithelialization [Numbers in all other columns can be transferred; "dito" should be changed to "ditto"] Note: 1: Animal group that was treated with Z2; 2: Animal group that was treated with ATP; 3: Control animal group. (**) - in parentheses, the number of eyes investigated. [0042] The figures given here are persuasive that the purulent discharges and the signs of the presence of s. aureus on the 4th day in all the animals treated with Z2 and on the 6th day in all animals treated with ATP had stopped. At the same time, the purulent discharges were observed in all the untreated animals over the entire period of the experiment. [0043] The resorption of the pus infiltrate began and ended 3 days sooner in all the animals that 14 were treated with Z2, and on the third and fifth days from the onset of treatment in all the animals treated with ATP. In all the animals that were treated with Z2 and ATP, the period from the onset to the end of resorption of the pus infiltrate were 4 days and 10 days, respectively, from the beginning of the treatment. Epithelialization of the cornea began in all the animals on approximately the 1 0 th day and on approximately the 16 th day from the onset of treatment with Z2 and ATP, respectively. [0044] Thus from the above figures, it can be concluded that Z2 is a highly effective means for the treatment of purulent inflammations of the cornea. The healing effect of Z2 is greater than that of ATP (eye drops per the prototype), which are being commercially produced (trade name "Okomistin"). Example 9 [0045] The anti-inflammatory effect was investigated. The rational composition of the combined salve that contains Z3 and 0.025% betamethasone was used for external treatment of allergic dermatoses. The same combination with the prototype produces no homogeneous consistency and cannot be used as a pharmaceutical preparation. [0046] The anti-inflammatory effect on the model of aerosil edema in rats was therefore investigated. Its effect was compared with the effect of the "Lorinden S" salve that is widely used for this purpose and with a control group (untreated). It was found that the development of swelling in rats treated with Z3 was 2.67 times less than in control animals and 1.14 times less than with the comparison preparation. The test results are shown in Table 6. Table 6 Anti-imflammatory effect of the salves Salve Number of rats Growth of rats' feet in g Inhibitor effect, in % Salve based on 12 0.124 ± 0.03 62.4 the preparation of the patent 15 application "Lorinden S" salve 12 0.141 ± 0.01 57.0 Control group 12 0.331± 0.02 (not treated) [0047] The figures given in Table 6 are persuasive that the Z# salve has an especially anti inflammatory effect. It reduces the aerosil edema by 62.4% on average, and its efficiency is somewhat superior to that of the comparable salve, "Lorinden S". Example 10 [0048] Investigations of the antiseptic properties of the suppository compound. [0049] The antibacterial effectiveness of Z 1 was investigated in comparison with the effectiveness of the ingredients during the in vitro tests by means of diffusion into the solid nutrient medium. [0050] During the experimental research, the following were selected as test microorganisms: e gram-positive cocci (Staphylococcus aureus ATCC 6538) * yeastlike fungi (Candida albicans ATCC 885-653). [0051] The control strain of Staphylococcus aureus ATCC 6538 was used for investigating the antibacterial effectiveness. This strain was procured from the D. K. Sabolotny Institute for Microbiology and Virology in Ukraine. [0052] For investigating the antifungal effectiveness, the control strain Candida albicans ATCC 885-653, procured from the same place, was used. Before the tests were performed, every culture was checked for purity. Also for each culture, its standard properties with regard to morphological and cultural features were checked. [0053] The antibacterial effectiveness was ascertained as follows, by diffusion into the agar: The 16 nutrient media were melted, cooled to a temperature of 45'C, and contaminated with the suspensions of the test cultures. [0054] The microbial load was approximately I x 10 7 KBE/ml. [0055] 20 ml of the medium contaminated with the microbes was poured into each of the petri dishes. After that, the medium was left to harden. Depressions averaging 8 mm were made in the layer with the nutrient medium, agar. [0056] The preparations to be investigated, Z 11, was melted at a temperature of 60'C, and 0.1 ml was placed in each of the previously prepared depressions. [0057] For comparison, suppositories with 0.07% of reference 20 (23) or 0.07% AO or 0.7% AA were prepared. [0058] For comparison, aqueous solutions of myramistin substance (reference 23) were investigated, in the concentrations corresponding to the preparations to be tested. [0059] Inoculations were made and incubated in the temperature regulators over the course of 24 hours at a temperature of 35'C. [0060] Once the incubation time had elapsed, the average was measured for those places on which the microorganisms showed no growth (inhibition zones). The depressions with the preparation were measured all the way around to an accuracy of 0.1 mm. Each test was made three times. [0061] The findings on the antibacterial effectiveness of the preparations to be investigated were ascertained during the in vitro test by means of a diffusion method and can be seen in Table 7.

17 Table 7 Suppositories Substance (myramistin) Name of preparation Average of inhibition Average of inhibition zones, in mm zones, in mm Staphylococcus Candida Staphylococcus Candida aureus albicans aureus albicans Myramistin, - - 9.6 9.0 0.07% aqueous solution Suppositories, 5.6 6.1 reference 23 AA 4.3 5.2 Z11 14.3 13.2 AO 1.2 2.1 [0062] From Table 7, the synergistic effect of the composition of this patent application is also apparent.

Claims

1. A pharmaceutical preparation, including benzyldimethyl-(3 [myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form, characterized in that it additionally contains dimethyl-(3-[myristoylamino]propyl)ammonium oxide and/or dimethyl ( 3 -[myristoylamino]propyl)amine in the appropriate pharmaceutical solvent.

2. The pharmaceutical preparation according to claim 1, characterized in that the proportion of the components is embodied as follows (in weight %): - benzyldimethyl-(3-[myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form 0.008 to 5.0 - dimethyl-( 3 -[myristoylamino]propyl)ammonium oxide and/or - dimethyl-(3-[myristoylamino]propyl)amine 0.00005 to 1.0 - the appropriate pharmaceutical solvent up to 100.

3. The pharmaceutical preparation according to claim 1, characterized in that the proportion of the components is embodied as follows (in weight %): - benzyldimethyl-(3-[myristoylamino]propyl)ammonium chloride in the form of monohydrate or in non-hydrated form 0.008 to 2.0 - dimethyl-(3-[myristoylamino]propyl)ammonium oxide and/or - dimethyl-(3-[myristoylamino]propyl)amine 0.00005 to 0.01 - the appropriate pharmaceutical solvent up to 100.

4. The pharmaceutical preparation according to claims 1-3, characterized in that it additionally contains a local anesthetic selected from the hydrochloride series comprising lidocaine, bupivacaine, pyromecaine, or trimecaine, in a quantity of from 0.1 to 5.0 weight %. 19

5. The pharmaceutical preparation according to claims 1-3, characterized in that it additionally contains sodium chloride in a quantity of from 0.6 to 1.0 weight %.

6. The pharmaceutical preparation according to claims 1-3, characterized in that it additionally contains an anti-edematous agent selected from the series comprising xylometazoline, oxymetazoline, naphazoline, phenylephrine, phenylpropanoloamine or pseudoephedrine in a quantity of from 0.01 to 2.0 weight %.

7. The pharmaceutical preparation according to claims 1-3, characterized in that it additionally contains corticosteroid selected from the series comprising triamcinolone, betamethasone or fluocinolone acetonide, hydrocortisone, halomethasone, or dexamethasone in a quantity of from 0.1 to 3.0 weight %.

8. The pharmaceutical preparation according to claims 1-3, characterized in that it additionally contains antiseptics and/or viricidal preparations selected from the series comprising metronidazole, clotrimazole, ketoconazole, acyclovir or rimantidine in a quantity of from 0.01 to 5.0 weight %.

9. The pharmaceutical preparation according to claims 1-8, characterized in that it contains alcohol and/or water as the pharmaceutical solvent.

10. The pharmaceutical preparation according to claims 1-8, characterized in that it contains an arbitrary liquid, gel-like salve base, detergent base or solid base of vegetable, animal or synthetic origin.

11. A method for treatment and prophylaxis of infectious and purulent inflammatory diseases of various etiology and location using the pharmaceutical preparation according to claims 1-10. 20

12. A method for treatment and prophylaxis of infectious, fungal and purulent inflammatory diseases of the eyes, the outer and inner ear, the oral cavity, and the nose and throat, and in dental medicine, using the pharmaceutical preparation according to claims 1-10.

13. A method for treatment and prophylaxis of infectious, fungal and purulent inflammatory diseases of the gastrointestinal tract and the urogenital system, using the pharmaceutical preparation according to claims 1-10.

14. A method for treatment and prophylaxis of infectious and purulent inflammatory diseases during the postoperative period involving intracavity and other operations, using the pharmaceutical preparation according to claims 1-10.

15. A method for treatment and prophylaxis of infectious, fungal and purulent inflammatory diseases and skin and mucous membrane bums, including dandruff, using the pharmaceutical preparation according to claims 1-10.

16. A method for treatment and prophylaxis of virogenic diseases, using the pharmaceutical preparation according to claims 1-10.